ReviewMarine drugs2024
Marine Lectins and Lectin-like Proteins as Promising Molecules Targeting Aberrant Glycosylation Signatures in Human Brain Tumors.
Review in Marine drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- C-Type Lectins from Marine Bivalves: Functional Diversity and Structural Insights.Marine drugs · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Glycosylation is a ubiquitous and the most structurally diverse post-translational modification of proteins. High levels of phenotypic heterogeneity in brain tumors affect the biosynthetic pathway of glycosylation machinery, resulting in aberrant glycosylation patterns. Traditionally, unique glycocode readers, carbohydrate-binding proteins, have been used to identify differentially expressed carbohydrate determinants associated with the tumor cell surface. However, identifying novel distinctive glycosylation signatures in brain tumors requires the timely development of molecular tools capable of targeting them. We classified marine-derived lectins and lectin-like molecules according to their ability to cover aberrant glycosylation patterns in brain tumors to encourage exploration of the potential of these molecules for precision diagnostics and personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.